CBU
HAE icon

CIBC Bancorp USA’s Haemonetics HAE Stock Holding History

CIBC Bancorp USA’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$251K Buy
+5,140
New +$318K ﹤0.01% 1161

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.82B AUM 7.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Bancorp USA's HAE Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Haemonetics (HAE) in Q3 2025: 5,140 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #1161 among its holdings.

301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

  • CIBC Bancorp USA held 5,140 shares of Haemonetics worth $251K as of Q3 2025.
  • Haemonetics was a new CIBC Bancorp USA position in Q3 2025.
  • Haemonetics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1161 holding.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.